1. 352 Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab. (10th December 2020) Authors: Cohen, Ezra; Postow, Michael; Sullivan, Ryan; Hong, David; Yeckes-Rodin, Heather; McCarter, Jerry; Zizlsperger, Nora; Kutok, Jeffery; O'Connell, Brenda; Page, Kara; Roberts, Jennifer; Zhang, Halle; Chmielowski, Bartosz Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 434 Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab. (9th November 2020) Authors: Postow, Michael; Sullivan, Ryan; Cohen, Ezra; Gutierrez, Martin; Hong, David; Steuer, Conor; McCarter, Jerry; Zizlsperger, Nora; Kutok, Jeff; O'Connell, Brenda; Roberts, Jennifer; Page, Kara; Zhang, Halle; Chmielowski, Bartosz Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A264 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 434 Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab. (9th November 2020) Authors: Postow, Michael; Sullivan, Ryan; Cohen, Ezra; Gutierrez, Martin; Hong, David; Steuer, Conor; McCarter, Jerry; Zizlsperger, Nora; Kutok, Jeff; O'Connell, Brenda; Roberts, Jennifer; Page, Kara; Zhang, Halle; Chmielowski, Bartosz Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A460 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia Masvidal; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine A.; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy A.;... Journal: Journal for immunotherapy of cancer Issue: Volume 4(2016)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina C.; Bajaj, Anshika; Archer, Jacob F.; Reeves, Rebecca S.; Ngo, Lisa Y.; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fu... Journal: Journal for immunotherapy of cancer Issue: Volume 4(2016)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience. (6th November 2014) Authors: Page, David B; Naidoo, Jarushka; Momtaz, Parisa; Bogatch, Kita; Kuk, Deborah; Panageas, Katherine; Yuan, Jianda; Wolchok, Jedd D; Postow, Michael Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. (March 2017) Authors: Wistuba-Hamprecht, Kilian; Martens, Alexander; Heubach, Florian; Romano, Emanuela; Geukes Foppen, Marnix; Yuan, Jianda; Postow, Michael; Wong, Phillip; Mallardo, Domenico; Schilling, Bastian; Di Giacomo, Anna Maria; Khammari, Amir; Dreno, Brigitte; Maio, Michele; Schadendorf, Dirk; Ascierto, Paol... Journal: European journal of cancer Issue: Volume 73(2017) Page Start: 61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone. Issue 1 (18th April 2017) Authors: Rosner, Samuel; Sen, Filiz; Postow, Michael Journal: Journal for immunotherapy of cancer Issue: Volume 5:Issue 1(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. (8th July 2016) Authors: Weber, Jeffrey S.; Postow, Michael; Lao, Christopher D.; Schadendorf, Dirk Journal: Oncologist Issue: Volume 21:Number 10(2016) Page Start: 1230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. Issue 1 (24th January 2022) Authors: Friedman, Claire F; Spencer, Christine; Cabanski, Christopher R; Panageas, Katherine S; Wells, Daniel K; Ribas, Antoni; Tawbi, Hussein; Tsai, Katy; Postow, Michael; Shoushtari, Alexander; Chapman, Paul; Karakunnel, Joyson; Bucktrout, Samantha; Gherardini, Pier; Hollmann, Travis J; Chen, Richard O... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗